- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT04979390
Safety, Tolerability and Pharmacokinetics of the New Formulation SHR-1316 in Subjects With Advanced Tumors
16. juli 2021 oppdatert av: Jiangsu HengRui Medicine Co., Ltd.
A Phase 1 Study to Evaluate the Safety, Tolerability and Pharmacokinetics of New Formulation SHR-1316 in Subjects With Advanced Tumors
The purpose of this study is to evaluate the safety, tolerability and pharmacokinetics of the new formulation SHR-1316 in subjects with advanced tumors.
Studieoversikt
Studietype
Intervensjonell
Registrering (Forventet)
15
Fase
- Fase 1
Kontakter og plasseringer
Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.
Studiekontakt
- Navn: Wen Jing
- Telefonnummer: 17721286191
- E-post: wen.jing@hengrui.com
Studer Kontakt Backup
- Navn: Yuya Wang
- Telefonnummer: 13918749176
- E-post: yuya.wang@hengrui.com
Deltakelseskriterier
Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
18 år og eldre (Voksen, Eldre voksen)
Tar imot friske frivillige
Nei
Kjønn som er kvalifisert for studier
Alle
Beskrivelse
Inclusion Criteria:
- Age ≥18 years.
- Histologically or cytologically confirmed advanced cancer in patients who are fail to current standard therapy or lack of effective therapy.
- Estimated life expectancy ≥12 weeks.
- Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
- Adequate organ functions.
- If of childbearing potential (male or female), agrees to practice an effective form of contraception during study treatment and for at least 3 months following last treatment dose.
- Patients must be willing and able to provide written informed consent prior to the performance of any study-specific procedure.
Exclusion Criteria:
- Known history of hypersensitivity to any components of the SHR-1316 product.
Patient- Prior treatment with the following agents:
- "Check-point inhibitors", including Programmed death receptor-1 (PD-1), PD-L1;
- Receipt of investigational agents within 4 weeks prior to study treatment;
- Current treatment on another therapeutic clinical trial, unless the observational (non-interventional) clinical trials or follow-up of interventional clinical trials;
- Any anti-cancer therapy (including chemotherapy, immunotherapy, hormone therapy, target therapy, biotherapy or tumor embolization), administered within 4 weeks prior to study treatment; or within 6 weeks in the case of certain therapies (e.g., mitomycin C and nitrosoureas). Any such, unless discussed and explained with the sponsor;
- Anticipated need for any anti-cancer therapy (including chemotherapy, immunotherapy, hormone therapy, or biotherapy) during SHR-1316 treatment; except palliative radiotherapy;
- Receipt of any anti-cancer vaccines; receipt of immunomodulatory drugs within 4 weeks prior to study treatment; topical, nasal spray and inhaled corticosteroids as well as systemic steroid therapy in physiological doses (such as: prednisone ≤10 mg/day) are acceptable.
- Patients have unrecovered (ie, to NCI CTCAE grade ≤1) from all toxicity associated with previous treatments (exception: patients may enter with continuing alopecia irrespective of CTCAE grade; grade 2 peripheral nerve diseases).
- Known Active central nervous system (CNS) metastases; Patients who had previously received brain or meningeal metastasis therapy, who were clinically stable for at least 8 weeks, and who had stopped systemic sex hormone therapy (such as: prednisone > 10 mg/day) for more than 4 weeks were included.
- Subjects with active autoimmune disease, history of autoimmune diseases, including but not limited to myasthenia gravis, autoimmune hepatitis, systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, etc.
- Active or history of immune deficiency, such as human immunodeficiency virus (HIV) infection; History of organ transplantation.
- History or evidence of cardiovascular (CV) risk including any of the following: Congestive heart failure (Class >2) as defined by the New York Heart Association functional classification system (NYHA), unstable angina pectoris, Recent (within the past 12 months) history of myocardial infarction, clinically significant supraventricular or ventricular arrhythmias need treatment or intervention.
- Patients with clinically significant ECG abnormalities (QT interval corrected for rate by Fridericia's formula [QTcF] >470 msec for female and >450 msec for male on the ECG obtained at Screening).
- Active infection that need drug intervention or an unexplained fever >38.5°C (fever caused by cancer can be included according to the judgement of the researcher).
- Active pulmonary tuberculosis infection.
- Positive for Hepatitis B or C.
- Known history of psychoactive drug abuse, alcohol abuse or drug use.
- Known history of any other malignant cancer within past 3 years. Exceptions: completely resected basal cell carcinoma and squamous cell carcinoma of the skin; and completely resected carcinoma in situ of cervix.
- Other severe acute or chronic medical or psychiatric condition or laboratory abnormality that may increase the risk associated with study participation or may interfere with the interpretation of study results and, in the judgment of the Investigator, would make the patient inappropriate for this study.
Studieplan
Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Grunnvitenskap
- Tildeling: N/A
- Intervensjonsmodell: Enkeltgruppeoppdrag
- Masking: Ingen (Open Label)
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
|---|---|
|
Eksperimentell: Behandlingsgruppe
|
SHR-1316 administrated intravenously (IV) at protocol defined dose levels
|
Hva måler studien?
Primære resultatmål
Resultatmål |
Tidsramme |
|---|---|
|
The incidence and severity of adverse events/serious adverse events (based on NCI-CTC AE 5.0)
Tidsramme: approximately 1 year
|
approximately 1 year
|
|
Maximum plasma concentration (Cmax)
Tidsramme: approximately 1 year
|
approximately 1 year
|
|
Time to maximum concentration (Tmax)
Tidsramme: approximately 1 year
|
approximately 1 year
|
|
Area under the concentration-time curve from time zero to time(AUC0-t)
Tidsramme: approximately 1 year
|
approximately 1 year
|
|
Area under the concentration-time curve extrapolated to infinity (AUC0-∞.)
Tidsramme: approximately 1 year
|
approximately 1 year
|
|
Elimination half-life (t1/2)
Tidsramme: approximately 1 year
|
approximately 1 year
|
|
Clearance (CL)
Tidsramme: approximately 1 year
|
approximately 1 year
|
|
Volume of distribution (Vz)
Tidsramme: approximately 1 year
|
approximately 1 year
|
|
Trough concentration (Cmin)
Tidsramme: approximately 1 year
|
approximately 1 year
|
|
Accumulatio of ratio (Rac)
Tidsramme: approximately 1 year
|
approximately 1 year
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Immunogenicity of SHR-1316
Tidsramme: approximately 1 year
|
Anti-SHR-1316 antibody (ADA), neutralizing antibody (Nab)
|
approximately 1 year
|
|
Objective response rate (ORR)
Tidsramme: approximately 1 year
|
approximately 1 year
|
|
|
Progression-free survival (PFS)
Tidsramme: approximately 1 year
|
approximately 1 year
|
|
|
Duration of response (DoR)
Tidsramme: approximately 1 year
|
approximately 1 year
|
|
|
Disease control rate (DCR)
Tidsramme: approximately 1 year
|
approximately 1 year
|
|
|
Overall survival (OS)
Tidsramme: approximately 1 year
|
approximately 1 year
|
Samarbeidspartnere og etterforskere
Det er her du vil finne personer og organisasjoner som er involvert i denne studien.
Studierekorddatoer
Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.
Studer hoveddatoer
Studiestart (Forventet)
10. august 2021
Primær fullføring (Forventet)
10. februar 2022
Studiet fullført (Forventet)
31. juli 2022
Datoer for studieregistrering
Først innsendt
12. juli 2021
Først innsendt som oppfylte QC-kriteriene
16. juli 2021
Først lagt ut (Faktiske)
28. juli 2021
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
28. juli 2021
Siste oppdatering sendt inn som oppfylte QC-kriteriene
16. juli 2021
Sist bekreftet
1. juli 2021
Mer informasjon
Begreper knyttet til denne studien
Andre studie-ID-numre
- SHR-1316-I-103
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Nei
Studerer et amerikansk FDA-regulert enhetsprodukt
Nei
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .